Data are reviewed from the phase 3 IMbrave150 trial for unresectable hepatocellular carcinoma.
EP. 1: Global Risk Factors and Incidence of HCC
Richard S. Finn, MD, provides insight on the key risk factors that lead to hepatocellular carcinoma.
EP. 2: Staging Liver Cancer
A review of prognostic factors and the importance of understanding underlying liver disease to help stage and treat patients with hepatocellular carcinoma.
EP. 3: Defining Resectability in HCC
Defining resectability in hepatocellular carcinoma based on burden of liver disease and Child-Pugh score.
EP. 4: Systemic Therapy Options for HCC
Richard S. Finn, MD, provides an overview of the systemic treatment options for advanced unresectable hepatocellular carcinoma.
EP. 5: IMbrave150 Leads to FDA Approval for HCC
Recent updates from the IMbrave150 study, which led to the FDA approval of frontline atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma [HCC].
EP. 6: Impressive Response Data from IMbrave150
Efficacy, safety, and quality of life data from IMbrave150 have changed the standard of care for unresectable hepatocellular carcinoma.
EP. 7: Looking to the Future in Unresectable HCC
Looking forward to further combinations and approaches for frontline and second-line therapy in advanced, unresectable hepatocellular carcinoma.
2 Clarke Drive Cranbury, NJ 08512